| Literature DB >> 23342263 |
Dan Dayan1, Tuula Salo, Sirpa Salo, Pia Nyberg, Sini Nurmenniemi, Daniela Elena Costea, Marilena Vered.
Abstract
We characterized tumor microenvironment (TME) components of mobile tongue (MT) cancer patients in terms of overall inflammatory infiltrate, focusing on the protumorigenic/anti-inflammatory phenotypes and on cancer-associated fibroblasts (CAFs) in order to determine their interrelations and associations with clinical outcomes. In addition, by culturing tongue carcinoma cells (HSC-3) on a three-dimensional myoma organotypic model that mimics TME, we attempted to investigate the possible existence of a molecular crosstalk between cancer cells and TME components. Analysis of 64 cases of MT cancer patients revealed that the overall density of the inflammatory infiltrate was inversely correlated to the density of CAFs (P = 0.01), but that the cumulative density of the protumorigenic/anti-inflammatory phenotypes, including regulatory T cells (Tregs, Foxp3+), tumor-associated macrophages (TAM2, CD163+), and potentially Tregs-inducing immune cells (CD80+), was directly correlated with the density of CAFs (P = 0.01). The hazard ratio (HR) for recurrence in a TME rich in CD163+ Foxp3+ CD80+ was 2.9 (95% CI 1.03-8.6, P = 0.043 compared with low in CD163+ Foxp3+ CD80+). The HR for recurrence in a TME rich in CAFs was 4.1 (95% confidence interval [CI] 1.3-12.8, P = 0.012 compared with low in CAFs). In vitro studies showed cancer-derived exosomes, epithelial-mesenchymal transition process, fibroblast-to-CAF-like cell transdifferentiation, and reciprocal interrelations between different cytokines suggesting the presence of molecular crosstalk between cancer cells and TME components. Collectively, these results highlighted the emerging need of new therapies targeting this crosstalk between the cancer cells and TME components in MT cancer.Entities:
Keywords: Cancer-associated fibroblasts; mobile tongue cancer; molecular crosstalk; myoma model; protumorigenic inflammatory cells
Mesh:
Year: 2012 PMID: 23342263 PMCID: PMC3544451 DOI: 10.1002/cam4.24
Source DB: PubMed Journal: Cancer Med ISSN: 2045-7634 Impact factor: 4.452
Antibodies for immunostains of the in vitro three-dimensional myoma and collagen gel assays
| Investigated pathways | Markers | Clone, working procedure | Manufacturer |
|---|---|---|---|
| Exosomal markers | TGF- | Polyclonal, 1:25, overnight, citrate buffer pH 6, pressure cooker | Acris, Herford, Germany |
| TSG 101 | Polyclonal, 1:30, overnight, EDTA pH 9, pressure cooker | Proteintech Group, Chicago, IL | |
| CAFs | Clone 1A4, 1:100, 60 min; citrate buffer, pH 6, microwave at 92°C | Dako A/S, Denmark | |
| Production and maintenance of inflammation | IL-1a | Polyclonal, 1:100, overnight, no antigen retrieval procedure needed | Acris, Herford, Germany |
| IL-8 | Polyclonal, 1:50, overnight, no antigen retrieval procedure needed | Proteintech Group, Chicago, IL | |
| IL-1R1 (CD121A) | Polyclonal, 1:50, overnight, EDTA pH 9, pressure cooker | Acris, Herford, Germany | |
| NF-kB | Polyclonal, NF-kB/p65 1:500, overnight, citrate buffer pH 6, pressure cooker | Alexis Biochemical San Diego, CA | |
| CXCL12 (SDF-1 | Clone 79018, 1:50, overnight, EDTA pH 9, pressure cooker | R&D Systems, Minneapolis, MN | |
| CXCR4 | Clone 44716, 1:50, overnight, EDTA pH 9, pressure cooker | R&D Systems, Minneapolis, MN | |
| CD80 | Clone 1G10, 1:50, overnight, citrate buffer pH 6, pressure cooker | Abcam, Cambridge, U.K. | |
| Foxp3 | Clone mAbcam 22510, 1:50, overnight, EDTA pH 9, pressure cooker | Abcam, Cambridge, U.K. | |
| EMT (double-stain) | Pan-cytokeratin (DAB) | AE1/AE3 (mouse), 1:50, overnight, citrate buffer pH 6, pressure cooker | Zymed/Invitrogen, Carlsbad, CA |
| – | |||
| Twist (fast red) | Polyclonal (rabbit), 1:50, overnight, citrate buffer pH 6, pressure cooker | Zytomed, Berlin, Germany | |
| – | |||
| Secondary antibody: HRP-AP rabbit, 45 min, room temperature | Innovex Biosciences, Richmond, CA |
CAF, cancer-associated fibroblasts; EMT, epithelial–mesenchymal transition; TGF-β, transforming growth factor-β; IL, interleukin; NF-kB, nuclear factor kappa-B; α-SMA, alpha smooth muscle actin; DAB, 3,3-diamino benzidine.
Figure 1(a) Density of the inflammatory infiltrate with a dense and continuous pattern, (b) a dense but discontinuous pattern, and (c) a lack of inflammatory infiltrate (hematoxylin and eosin, original magnification 40×). (d) Samples of specific types of inflammatory cells comprised pan T lymphocytes, (e) CD4 lymphocytes, (f) CD8 lymphocytes, (g) B lymphocytes, (h) plasma cells, arrows (positive immunostaining also seen in the tumor islands), (i) CD68 macrophages, (j) CD163 macrophages, (k) CD163 stromal cells (arrows), (l) regulatory T cells (Foxp3-positive), and (m) CD80-positive cells. Nuclear NF-kB was present in both the tumor cells and the inflammatory cells (n). Photomicrographs (d–n) were at 100× original magnification with the exception of (m), which was at 200×.
Figure 2(a) Kaplan–Meier analysis for locoregional recurrence by Foxp3. (b) Kaplan–Meier analysis for locoregional recurrence by the cumulative score of CD163+ CD80+ Foxp3+. (c) Kaplan–Meier analysis for locoregional recurrence by CAF. (d) Kaplan–Meier analysis for overall survival by CAF scores.
Figure 3(a and b) Myoma model and collagen assay. Hematoxylin and eosin stain shows a collagenous “collar-like” area that surrounds the tumor islands (arrows) that invade into the smooth muscle tissue of the myoma (M) (original magnification 200×). (c) TSG101 in the myoma model shows a strong and diffuse staining of the superficial lining and deeply invading tumor islands/clusters (original magnification 100×). (d) The stromal cells surrounding the tumor island are also TSG101 positive when seen at a higher magnification (original magnification 400×). (e) Both the HSC-3 cells and fibroblasts are TSG101 positive in the collagen assay (original magnification 100×). (f and g) TGF-β immunostain in the myoma assay (original magnification 100× and original magnification 400×, respectively) and (h) in the collagen assay (original magnification 100×) exhibit a similar pattern of expression as TSG101. (i) α-SMA staining in a sample of monoculture: a tumor island is surrounded at its periphery by delicate, spindle-shaped α-SMA-positive cells (arrows). (j) A sample of coculture of HSC-3 cells and CaDEC cells: small invading tumor islands (arrows) are closely surrounded by concentric layers of α-SMA-positive cells. (k) No α-SMA-positive cells were found in the collagen assay (i, j, and k, original magnification 400×). (l) Double immunostaining with pan-cytokeratin (CK) (brown) and twist (red–purple): the same field as illustrated in (i), shows that those α-SMA-positive cells are both pan-CK and twist positive. (m) The same field as illustrated in (j) shows that those cells positive for α-SMA are twist positive. (n) No stromal cells were seen at the tumor–stroma interface in the collagen assay, as was the case for (k). (l, m, and n, original magnification 400×).
In vitro immunoreactivity of the HSC-3 cell line and the stromal components
| TGS101 | TGF- | IL-1a | IL-8 | NF-kB | CXCR4 | CXCL12 | CD80 | Foxp3 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T | F/M | T | F/M | F/M | T | F/M | T | F/M | T | F/M | T | F/M | T | F/M | T | F/M | T | F/M | |
| Myoma | 2 | 1 | * | 0 | 2nc | 2 | 4 | 0 | 0 | 0 | |||||||||
| 4 | 1 | * | 0 | 2nc | 1 | 4 | 0 | 0 | 0 | ||||||||||
| Myoma + GF | 2 | 1 | * | − | 2nc | 3 | 4 | 0 | 0 | 0 | |||||||||
| 4 | 2 | * | 0 | − | 3 | 4 | 0 | 0 | 0 | ||||||||||
| Myoma + HSC-3 | 4 | 4 | 4 | 1 | *, CAF | 1nc | 0 | 4cn | 2nc | 4 | 2 | 4 | 4 | 0 | 0 | 4 | 0 | 0 | 0 |
| 4 | 2 | 4 | 2 | *, CAF | 4nc | 0 | 2cn | 2cn | 4 | 2 | 4 | 4 | 0 | 0 | 3 | 0 | 0 | 0 | |
| Myoma + HSC-3 + GF | 2 | 1 | 4 | 2 | * | 4nc | 0 | 4nc | 2c | 4 | 1 | 4 | 4 | 0 | 0 | 4 | − | 0 | − |
| 2 | 2 | 2 | 1 | * | 4nc | 0 | 4cn | 4nc | 4 | 2 | 2 | 4 | 0 | 0 | 4 | 0 | 0 | 0 | |
| Myoma + HSC-3 + CaDEC | 4 | 2 | 4 | 2 | *, CAF | 4nc | 0 | 4cn | 2cn | 4 | 2 | 4 | 4 | 1 | 0 | 1 | 0 | 1 | 0 |
| 2 | 2 | 2 | 1 | *, CAF | 4nc | 0 | 4cn | 2c | 4 | 2 | 4 | 4 | 1 | 0 | 2 | 0 | 0 | 0 | |
| Collagen + GF | 4 | 4 | 0 | 2c | 4nc | 4 | 4 | 0 | 0 | 0 | |||||||||
| 4 | 2 | 0 | 4c | 4cn | 4 | 4 | 1 | 3 | 2 | ||||||||||
| Collagen + HSC-3 + GF | 4 | − | 4 | − | 0 | 4c | 4nc | 4cn | 4cn | 4 | − | 4 | − | 0 | 0 | 2 | − | 1 | 1 |
| 4 | 4 | 4 | 4 | 0 | 4c | 4c | 4n | 4c | 2 | 1 | 4 | 4 | 0 | 0 | 1 | 1 | 1 | 1 | |
| Collagen + HSC-3 + GF | 4 | 4 | 4 | 4 | 0 | 4c | 4cn | 4cn | 4cn | 4 | 4 | 4 | 4 | 0 | 0 | 2 | 2 | 2 | 2 |
| 4 | 4 | 4 | 4 | 0 | 4c | 4c | 4cn | 4cn | 4 | 4 | 2 | 2 | 0 | 0 | 4 | 3 | 2 | 2 | |
The numbers refer to the scoring system (0 = no staining, 1 = staining of weak intensity in <50% cells, 2 = weak but extensive [>50% cells] staining, 3 = strong staining in <50% cells, and 4 = strong staining in >50% cells).
IL-1R1 (CD121A) staining was positive in all examined sections with a score of 4 (see text) in the HSC-3 cells as well as in the fibroblasts/myoma cells and therefore was not included in this table.
T, tumor; F/M, fibroblasts/myoma cells; GF, gingival fibroblasts; CaDEC12, CAF cell line; c, cytoplasmic staining; n, nuclear staining; cn, cytoplasmic staining more frequent than nuclear staining; nc, nuclear staining more frequent than cytoplasmic staining; (−), no staining; *, the myoma smooth muscle cells were positive.
Figure 4Immunohistochemical stains of the myoma model and collagen assay for IL-1a (a and b), IL-8 (c and d), NF-kB (e and f), IL-1R1 (g and h), and CXCR4 (i and j) (a, c, e, g, and i, original magnification 40×; b, d, f, h, and j, original magnification 100×).